MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 585073 | Name: JTP 103237
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

JTP 103237 is a potent and selective monoacyglycerol acyltransferase 2 (MOGAT2) inhibitor.

Chemical Structure

JTP 103237
JTP 103237
CAS#1883864-16-1

Theoretical Analysis

MedKoo Cat#: 585073

Name: JTP 103237

CAS#: 1883864-16-1

Chemical Formula: C24H29F3N6O

Exact Mass: 474.2355

Molecular Weight: 474.53

Elemental Analysis: C, 60.75; H, 6.16; F, 12.01; N, 17.71; O, 3.37

Price and Availability

Size Price Availability Quantity
10mg USD 450.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
JTP 103237; JTP103237; JTP-103237
IUPAC/Chemical Name
7-[4,6-Bis(1,1-dimethylethyl)-2-pyrimidinyl]-5,6,7,8-tetrahydro-3-[4-(trifluoromethoxy)phenyl]-1,2,4-triazolo[4,3-a]pyrazine
InChi Key
KELNXHBJTXCXSN-UHFFFAOYSA-N
InChi Code
InChI=1S/C24H29F3N6O/c1-22(2,3)17-13-18(23(4,5)6)29-21(28-17)32-11-12-33-19(14-32)30-31-20(33)15-7-9-16(10-8-15)34-24(25,26)27/h7-10,13H,11-12,14H2,1-6H3
SMILES Code
FC(F)(F)OC1=CC=C(C2=NN=C3CN(C4=NC(C(C)(C)C)=CC(C(C)(C)C)=N4)CCN32)C=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Potent and selective monoacyglycerol acyltransferase 2 (MOGAT2) inhibitor.
In vitro activity:
TBD
In vivo activity:
In the present study, JTP-103237 prevented carbohydrate-induced fatty liver and suppressed both TG synthesis and de novo lipogenesis, suggesting MGAT inhibitor may prevent carbohydrate-induced metabolic disorders, including NAFLD, obesity and diabetes. The results showed that JTP-103237 significantly decreased hepatic triglyceride (45.0 ± 5.5 mg/g liver in vehicle group and 27.1 ± 7.3 mg/g liver, respectively. P < 0.01 in Student's t-test) in mice. Reference: J Pharmacol Sci. 2015 Jul;128(3):150-7. https://pubmed.ncbi.nlm.nih.gov/26215699/
Solvent mg/mL mM
Solubility
DMSO 9.5 20.00
Ethanol 47.5 100.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 474.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Okuma C, Ohta T, Tadaki H, Ishigure T, Sakata S, Taniuchi H, Sano R, Hamada H, Kume S, Nishiu J, Kakutani M. JTP-103237, a monoacylglycerol acyltransferase inhibitor, prevents fatty liver and suppresses both triglyceride synthesis and de novo lipogenesis. J Pharmacol Sci. 2015 Jul;128(3):150-7. doi: 10.1016/j.jphs.2015.06.007. Epub 2015 Jul 2. PMID: 26215699.
In vitro protocol:
TBD
In vivo protocol:
1. Okuma C, Ohta T, Tadaki H, Ishigure T, Sakata S, Taniuchi H, Sano R, Hamada H, Kume S, Nishiu J, Kakutani M. JTP-103237, a monoacylglycerol acyltransferase inhibitor, prevents fatty liver and suppresses both triglyceride synthesis and de novo lipogenesis. J Pharmacol Sci. 2015 Jul;128(3):150-7. doi: 10.1016/j.jphs.2015.06.007. Epub 2015 Jul 2. PMID: 26215699.
Okuma et al (2015) JTP-103237, a novel monoacylglycerol acyltransferase inhibitor, modulates fat absorption and prevents diet-induced obesity. Eur.J.Pharmacol. 758 72 PMID: 25857225 Okuma et al (2015) JTP-103237, a monoacylglycerol acyltransferase inhibitor, prevents fatty liver and suppresses both triglyceride synthesis and de novo lipogenesis. J.Pharmacol.Sci. 128 150 PMID: 26215699

View History

Pyraclostrobin

Pyraclostrobin